Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis.

TitleApolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis.
Publication TypeJournal Article
Year of Publication2023
AuthorsAdaku N, Ostendorf BN, Mei W, Tavazoie SF
JournalCancer Res
Volume83
Issue18
Pagination3013-3025
Date Published2023 Sep 15
ISSN1538-7445
KeywordsAlzheimer Disease, Animals, Apolipoprotein E2, Apolipoprotein E3, Apolipoprotein E4, Apolipoproteins E, Carrier Proteins, Humans, Melanoma, Mice
Abstract

UNLABELLED: The secreted lipid transporter apolipoprotein E (APOE) plays important roles in atherosclerosis and Alzheimer's disease and has been implicated as a suppressor of melanoma progression. The APOE germline genotype predicts human melanoma outcomes, with APOE4 and APOE2 allele carriers exhibiting prolonged and reduced survival, respectively, relative to APOE3 homozygotes. While the APOE4 variant was recently shown to suppress melanoma progression by enhancing antitumor immunity, further work is needed to fully characterize the melanoma cell-intrinsic effects of APOE variants on cancer progression. Using a genetically engineered mouse model, we showed that human germline APOE genetic variants differentially modulate melanoma growth and metastasis in an APOE2>APOE3>APOE4 manner. The low-density lipoprotein receptor-related protein 1 (LRP1) receptor mediated the cell-intrinsic effects of APOE variants on melanoma progression. Protein synthesis was a tumor cell-intrinsic process differentially modulated by APOE variants, with APOE2 promoting translation via LRP1. These findings reveal a gain-of-function role for the APOE2 variant in melanoma progression, which may aid in predicting melanoma patient outcomes and understanding the protective effect of APOE2 in Alzheimer's disease.

SIGNIFICANCE: APOE germline variants impact melanoma progression through disparate mechanisms, such as the protein synthesis-promoting function of the APOE2 variant, indicating that germline genetic variants are causal contributors to metastatic outcomes.

DOI10.1158/0008-5472.CAN-23-1252
Alternate JournalCancer Res
PubMed ID37335131
PubMed Central IDPMC10740391
Grant ListR01 CA184804 / CA / NCI NIH HHS / United States
U54 CA261701 / CA / NCI NIH HHS / United States
R35 CA274446 / CA / NCI NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
F30 CA257226 / CA / NCI NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States

Person Type: